Skip to Content

A frontline fighter in the war against microbes.

The bugs that make us sick are increasingly resistant to the drugs we’ve used (and misused) to fight them. By one estimate, antimicrobial resistance (AMR) will cause the deaths of 10 million people annually by 2050. BD’s products, including its test to rapidly detect drug-resistant tuberculosis and its infection-prevention equipment, are tools to combat AMR. BD also trains health workers to quickly and precisely diagnose and treat infection. In Uganda, with BD’s help, turnaround time for a TB test has fallen from three weeks to three days, reducing chances that a patient will go untreated or be given the wrong drug.

Company Information

Country
U.S.
Headquarters
Franklin Lakes, N.J.
Impact Segment
Public Health/Nutrition
Sector
Healthcare
Industry
Medical Products and Equipment
CEO
Vincent Forlenza
Websitehttp://www.bd.com
Company Type
Public
Ticker
BDX
Prior Year Rank-
Revenues ($M) (Last Fiscal Year)$15,983
Profits ($M) (Last Fiscal Year)$311
Market Value ($M) as of 8/12/19$67,262
Employees76,032

Refinitiv Sustainable Leadership Monitor

placeholder